OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $24.4444.

KIDS has been the topic of a number of research analyst reports. BTIG Research reiterated a “buy” rating and set a $24.00 target price on shares of OrthoPediatrics in a report on Friday, May 1st. Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a report on Friday, April 24th. Needham & Company LLC upped their target price on OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Tuesday, April 21st.

Insider Transactions at OrthoPediatrics

In other news, CEO David R. Bailey sold 19,535 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $336,978.75. Following the sale, the chief executive officer directly owned 298,020 shares of the company’s stock, valued at $5,140,845. The trade was a 6.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gregory A. Odle sold 8,433 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $145,469.25. Following the completion of the sale, the insider directly owned 187,735 shares in the company, valued at approximately $3,238,428.75. This represents a 4.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 58,171 shares of company stock worth $1,003,450. Company insiders own 32.70% of the company’s stock.

Institutional Trading of OrthoPediatrics

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its position in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Caption Management LLC bought a new stake in shares of OrthoPediatrics in the 3rd quarter worth approximately $54,000. BNP Paribas Financial Markets boosted its position in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of OrthoPediatrics by 189.7% in the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after purchasing an additional 4,467 shares in the last quarter. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Stock Down 3.4%

KIDS stock opened at $17.83 on Friday. OrthoPediatrics has a fifty-two week low of $14.42 and a fifty-two week high of $23.70. The business’s 50 day moving average price is $17.09 and its two-hundred day moving average price is $17.43. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21. The company has a market capitalization of $457.87 million, a price-to-earnings ratio of -10.61 and a beta of 1.03.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%.The firm had revenue of $59.36 million for the quarter, compared to the consensus estimate of $58.29 million. As a group, analysts forecast that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.